Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Efficacy and Safety Study of IFX-1 in Add-On to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs IFX 1 (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Granulomatosis with polyangiitis; Microscopic polyangiitis
- Focus Adverse reactions
- Sponsors InflaRx
- 08 May 2019 According to an InflaRx media release, the company intends to use the net proceeds of approximately $57.1 million from the offering of common shares to conduct Phase II clinical development program for IFX-1 in AAV patients as well as to fund first clinical Phase II development in two additional neutrophil-driven indications within the autoimmune and inflammatory disease area and the remainder to fund other research and development activities.
- 28 Mar 2019 According to an InflaRx media release, first patient was dosed in October 2018.
- 25 Oct 2018 New trial record